(2S)-3-phenyl-2-(1,3-thiazol-4-ylmethylamino)-N-[5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-yl]propanamide | 1401460-39-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-3-phenyl-2-(1,3-thiazol-4-ylmethylamino)-N-[5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-yl]propanamide
• CAS: 1401460-39-6
• 化学式: C₁₈H₁₆N₆OS₃
• 分子量: 428.563
• InChiKey: JOSQCIRAOBHESO-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  177
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (1,3-Thiazole-5-carbonylamino)thiourea 在 三乙酰氧基硼氢化钠 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三氟乙酸 作用下， 反应 1.0h， 生成 (2S)-3-phenyl-2-(1,3-thiazol-4-ylmethylamino)-N-[5-(1,3-thiazol-5-yl)-1,3,4-thiadiazol-2-yl]propanamide
  参考文献：
  名称：

  Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes

  摘要：

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.015

文献信息

• Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes
  作者：Xiaohui Du、Yong-Jae Kim、SuJen Lai、Xi Chen、Mike Lizarzaburu、Simon Turcotte、Zice Fu、Qingxiang Liu、Ying Zhang、Alykhan Motani、Kozo Oda、Ryo Okuyama、Futoshi Nara、Michiko Murakoshi、Angela Fu、Jeff D. Reagan、Peter Fan、Yumei Xiong、Wang Shen、Leping Li、Jonathan Houze、Julio C. Medina

  DOI：10.1016/j.bmcl.2012.08.015

  日期：2012.10

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.